CD30, Th2 cytokines and HIV infections: a complex and fascinating link

doi:10.1016/0167-5699(95)80092-1

Immunology Today

Volume 16, Issue 2, 1995, Pages 76-80

Immunology Today

https://doi.org/10.1016/0167-5699(95)80092-1 Get rights and content

Abstract

CD30 is a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) receptor superfamily, and was originally described as a marker of Hodgkin's and Reed-Sternberg cells in Hodgkin's lymphoma. CD30 is preferentially expressed on CD4⁻ and CD8⁺ T-cell clones that produce T helper 2 (Th2)-type cytokines, and is also released in a soluble form by these cells. Elevated serum levels of soluble (s)CD30 have been found in some conditions in which a pathogenic role for Th2 cells has been suggested, such as atopy, Omenn's syndrome, systemic lupus erythematosus, as well as following infection with measles virus or human immuno-deficiency virus (HIV). Here, Gianfranco Del Prete and colleagues suggest a complex and fascinating link between the expression and release of CD30, and the immunopathogenesis of HIV infection.

References (40)

DurkopH. et al.
Cell
(1992)
SteinH. et al.
Blood
(1985)
AndreesenR. et al.
Blood
(1984)
RomagnaniS.
Immunol. Today
(1991)
GauseA. et al.
Blood
(1991)
GoldmanM. et al.
Immunol. Today
(1991)
RomagnaniS.
Curr. Opin. Immunol.
(1994)
KapsenbergM.L. et al.
Immunol. Today
(1991)
WardB.J. et al.
Clin. Immunol. Immunopathol.
(1993)
ClericiM. et al.
Immunol. Today
(1993)

SmithC.A. et al.

Cell

(1993)

SmithC. et al.

Science

(1990)

BeutlerB. et al.

Science

(1994)

FroeseP. et al.

J. Immunol.

(1987)

NawrockiJ.F. et al.

J. Immunol.

(1988)

Josimovic-AlasevicO. et al.

Eur. J. Immunol.

(1989)

SchwabU. et al.

Nature

(1982)

EllisT.M. et al.

J. Immunol.

(1993)

MosmannT.R. et al.

Annu. Rev. Immunol.

(1989)

Del Prete, G.F., De Carli, M., Almerigogna, F. et al. FASEB J. (in...

Cited by (146)

TNF superfamily: Costimulation and clinical applications
2009, Cell Biology International
Citation Excerpt :
As noted in the case of CD27, the soluble form of CD30 (∼85/88 kDa) is generated when membrane-bound CD30 protein is cleaved by zinc metalloproteinase (Hansen et al., 1995). Interestingly, soluble CD30 (sCD30) shedding can be found in several neoplastic and reactive diseases (Del Prete et al., 1995; Falini et al., 1995; Pizzolo et al., 1994, 1997; Romagnani et al., 1995) but the significance of sCD30 is not clear. In atopic dermatitis, CD30+ infiltrating T cells in lesions, elevated sCD30 levels, and increased number of circulating CD30+ cells were reported (Dummer et al., 2003).
The molecules concerned with costimulation belong either to the immunoglobulin (Ig) or tumor necrosis factor (TNF) superfamily. The tumor necrosis superfamily comprises molecules capable of providing both costimulation and cell death. In this review we briefly summarize certain TNF superfamily receptor–ligand pairs that are endowed with costimulatory properties and their importance in health and disease.
HIV, 'An evolving species'. Roles of cellular activation and co-infections
2003, Medical Hypotheses
Each small variation of the genome of a species can be preserved if it is useful for the survival of the species in a given environment. Within this framework, the finality of the biological cycle of HIV consists in a search for harmony (biological coherence) with man, which is to say a stable condition. Cellular activation appears to be the strategy developed by HIV in order to achieve this coherence. The price of this strategy is the AIDS. The first contact between HIV and immune system appears to determine the subsequent clinical outcome and the future of HIV. Lymphocytic activation varies during the course of the vital cycle of HIV. For each individual, this lymphocytic activation depends on both the HLA repertoire acquired during thymic ontogenesis and the antigenic experience before and after HIV infection. Thus intercurrent infections alter the immune condition of the organism and influence the outcome of HIV. We described a synthetic analysis of the effects of HIV on the surface protein expression and the cellular activation pathways which should provide insights in the evolutionary relationship between HIV and man and should permit to do a more physiological therapeutic approach.
Regulation of lymphocyte clustering by CD30-mediated ICAM-1 up-regulation
2002, Cellular Immunology
CD30 is expressed transiently on activated B and T lymphocytes and constitutively on several B- and T cell lymphomas. CD30 functions include participation in negative selection of thymocytes, costimulation of activated T cells, isotype switching of B cells, and regulation of the effector activity of cytotoxic lymphocytes. Although CD30 is not a marker for T helper 2 (TH2) cells, it may participate in the polarization of TH1 and TH2 cells. The pleiotropic functions of CD30 are initiated by interaction of CD30-expressing cells with other immune competent cells expressing CD30-L and providing the signals for modulation of effector cell activity. Here, we report that CD30 signals generated by anti-CD30 on activated, normal murine T cells strongly up-regulate the expression of intercellular adhesion molecule 1 (ICAM-1, CD54), and to a lesser extent, ICAM-2 (CD102). CD30 signals moreover delay the subsequent decline of ICAM expression. CD30 cross-linking did not alter the expression of CD11a/CD18 (LFA-1), the counter receptor for ICAM abundant on T cells. CD30-mediated ICAM-1 up-regulation is independent of cytokine secretion and appears to be transmitted directly through NF-κB activation. CD30-mediated up-regulation of ICAM-1 expression led to a significant increase in cluster formation of lymph node cells. Increased lymphocyte self-aggregation mediated by CD30 may set the stage for fraternal signaling to modulate lymphocyte function.
Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review
2020, Current Hematologic Malignancy Reports
Association of high levels of plasma OX40 with acute adult T-cell leukemia
2019, International Journal of Hematology
Elevated levels of soluble CD26 and CD30 in multiple sclerosis
2015, Clinical and Experimental Neuroimmunology

View all citing articles on Scopus

: We wish to thank: F. Almerigogna, F. Annunziato, R. Biagiotti, M. Chilosi, K. Daniel, M. De Carli, M.M. D'Elios, L Giannarini, M.G. Giudizi, R. Manetti, M. Mazzetti, L. Morosato, P. Parronchi, M-P. Piccinni, A. Ravina, S. Sampognaro, F. Vinante and G. Zancuoghi for their valuable collaboration. We also wish to thank D. Cosman and M. Alderson (Immunex, Seattle, Washington) for providing the M44 anti-CD30 and the M81 anti-CD30L mAbs, and H. Stein (Freie Universitat, Berlin, Germany) for helpful discussion. The experiments reported in this paper have been performed by grants provided by AIRC, Istituto Superiore di Sanità(AIDS Project), CNR (FATMA and ACRO Projects) and EU (Biotech Projects).

¹: Gianfranco Del Prete, Enrico Maggi and Sergio Romagnani are at the Division of Clinical Immunology and Allergy, Universitty of Florence, 50134 Florence, Italy; Giovanni Pizzolo is at the Division of Hematology, University of Verona, 37134 Verona, Italy.

View full text

CD30, Th2 cytokines and HIV infections: a complex and fascinating link

Abstract

Cell

Blood

Blood

Immunol. Today

Blood

Immunol. Today

Curr. Opin. Immunol.

Immunol. Today

Clin. Immunol. Immunopathol.

Immunol. Today

Cell

Science

Science

J. Immunol.

J. Immunol.

Eur. J. Immunol.

Nature

J. Immunol.

Annu. Rev. Immunol.